Latest news
Takeda’s LIVTENCITY CMV Study in Japan: What Investors Should Watch - TipRanksTipRanks · Fri, 07 Aug 2026 16:38:26 GMTFDA approves Takeda’s Orzeyful to treat narcolepsy type 1 in adults - TipRanksTipRanks · Wed, 05 Aug 2026 21:03:39 GMTTakeda Tracks Real World Safety of Ceprotin (TAK-662) in Rare Clotting Disorder - TipRanksTipRanks · Fri, 31 Jul 2026 17:17:56 GMTPress Release: Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track - MoomooMoomoo · Thu, 30 Jul 2026 17:39:05 GMTTakeda Pharmaceutical Q1 Earnings Call Highlights - TradingViewTradingView · Thu, 30 Jul 2026 12:03:52 GMTTakeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track - Business WireBusiness Wire · Thu, 30 Jul 2026 07:00:00 GMTSolid first quarter performance for Takeda - The Pharma LetterThe Pharma Letter · Thu, 30 Jul 2026 07:00:00 GMTTakeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $19.01, Implies 9% Upside - TradingViewTradingView · Tue, 28 Jul 2026 17:20:12 GMT